AIM ImmunoTech
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2117 SW Hwy 484, Ocala, Florida, 34473, ...Phone Number
(352) 448-7797Website
www.aimimmuno.comRevenue
<$5 MillionStock Symbol
AIMIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companys lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.Explore more
AIM ImmunoTech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AIM ImmunoTech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AIM ImmunoTech has new funding data
Earning: See what the market has to say on AIM ImmunoTech recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if AIM ImmunoTech has recently received funding, and reach out quickly before it becomes old news!
Click to see if AIM ImmunoTech had a recent Job posting/layoffs
Check out if AIM ImmunoTech is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at AIM ImmunoTech
AIM ImmunoTech, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AIM ImmunoTech launches new products
Recommended Actions
Reach out to Masked Content who joined AIM ImmunoTech as Masked Content
Find more new buyers
Compare Similar Companies to AIM ImmunoTech
Compare insights from companies similar to AIM ImmunoTech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AIM ImmunoTech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AIM ImmunoTech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AIM ImmunoTech.
AIM ImmunoTech Tech Stack
A closer look at the technologies used by AIM ImmunoTech
See more technologies
Most Recent Scoops
Project
AIM ImmunoTech has identified two key biomarker stratifications in its pancreatic cancer program a neutrophil-lymphocyte ratio of less than 4.5, associated with a median overall survival improvement of 22 months, and a CA 19-9 tumor marker threshold, associated with an overall survival improvement of 11.6 months highlighting the potential of Ampligen for a significant segment of the patient population.
Medical Research
Partnership
AIM ImmunoTech has entered into a collaboration agreement with AstraZeneca and Erasmus University Medical Center to conduct the DURAPANC Phase II trial, combining Ampligen with AstraZeneca's PD-L1 checkpoint inhibitor durvalumab for the treatment of metastatic pancreatic cancer.
Partnership
Project
AIM ImmunoTech has secured a U.S. patent for Ampligen in combination with PD-L1 checkpoint inhibitors for the treatment of cancers, including pancreatic cancer, and has been granted orphan drug designations in both the European Union and the United States, providing extended market exclusivity in those regions.
Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Project
AIM ImmunoTech has completed the MB-107 clinical trial of Anti-micin to treat soft tissue sarcoma lung metastases, delivering an overall survival of 13.5 months in very late-stage patients receiving an average of seventh-line treatment.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
AIM ImmunoTech News & Media
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
Live webcast on Wednesday, June 24th at 2:40 PM ET Live webcast on Wednesday, June 24th at 2:40 PM ETAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancerAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained compliance with NYSE American’s continued listing standards related to stockholders’ equity.AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting placement agent commissions and other offering expenses.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AIM ImmunoTech
Sign Up For FreeTo access detailed company insights
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companys lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers,... Read More
